List of Excipients in Branded Drug CYCLOBENZAPRINE HCL ER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	DIETHYL PHTHALATE
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	ETHYLCELLULOSE
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C BLUE NO. 1
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C BLUE NO. 2
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C RED NO. 40
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C YELLOW NO. 6
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	GELATIN

Cyclobenzaprine HCl ER Excipient Strategy and Commercial Opportunities

Last updated: September 19, 2026

Cyclobenzaprine hydrochloride extended release is a mature small-molecule product with limited remaining value from primary composition-of-matter patents. Commercial opportunities are concentrated in differentiated extended-release delivery, lower-cost multiparticulate manufacturing, improved tolerability, alternative dosage forms, and regulatory-friendly reformulations. The main reference product is Amrix, a once-daily 15 mg or 30 mg extended-release capsule. Generic ER competition has reduced the value of the original branded product, while immediate-release cyclobenzaprine remains widely available.

What is the regulatory status of cyclobenzaprine HCl ER?

Cyclobenzaprine HCl ER was approved by the FDA as Amrix under NDA 021777. The product is indicated for the relief of muscle spasm associated with acute, painful musculoskeletal conditions and is intended for short-term use, generally up to two or three weeks.[1]

Attribute	Cyclobenzaprine HCl ER
Reference product	Amrix
Active ingredient	Cyclobenzaprine hydrochloride
Dosage form	Extended-release capsule
Strengths	15 mg and 30 mg
Administration	Once daily
FDA pathway	NDA for originator; ANDA pathway for generics
Therapeutic class	Centrally acting skeletal muscle relaxant
Main comparator	Immediate-release cyclobenzaprine tablets
Primary commercial issue	Differentiation against low-cost immediate-release and generic ER products

The FDA label describes Amrix as an extended-release capsule intended to provide once-daily dosing. The product should not be substituted on a milligram-for-milligram basis with immediate-release cyclobenzaprine without accounting for the different release profiles.[1]

Cyclobenzaprine is structurally related to tricyclic antidepressants. Its adverse-effect profile includes drowsiness, dry mouth, dizziness, and anticholinergic effects. Those characteristics make release-rate control and peak exposure important formulation considerations.

What excipients are used in cyclobenzaprine HCl ER?

The Amrix formulation uses a multiparticulate extended-release design rather than a simple immediate-release powder-filled capsule. The product contains coated particles or pellets that control dissolution over the intended dosing interval. The FDA-approved labeling identifies inactive ingredients that include hypromellose, ethylcellulose, povidone, sugar spheres, talc, gelatin, titanium dioxide, and capsule colorants, with excipient composition varying by strength and component.[1]

Excipient or excipient class	Likely formulation function
Sugar spheres	Inert cores for drug-layered pellets
Hypromellose	Film former, viscosity modifier, or release-controlling polymer
Ethylcellulose	Water-insoluble diffusion-control coating
Povidone	Binder for drug layering or granulation
Talc	Anti-tacking and coating-process aid
Gelatin	Hard capsule shell
Titanium dioxide	Opacifier and appearance control
Colorants	Strength identification and product differentiation

The commercial value of this architecture is its ability to divide the dose across multiple coated units. Multiparticulate systems can reduce the impact of localized manufacturing defects, support more reproducible release, and provide a platform for combining different release populations. They also create technical barriers around coating uniformity, pellet size distribution, drug loading, and dissolution matching.

Excipient selection must comply with the FDA Inactive Ingredient Database, compendial requirements, and dose-specific exposure precedents. The FDA database provides historical route and dosage-form information but does not by itself establish approval for every concentration or formulation.[2]

What excipient strategy is most suitable for a new cyclobenzaprine ER product?

The strongest general strategy is a multiparticulate, diffusion-controlled capsule with a narrow and well-characterized release profile.

Multiparticulate coated-pellet strategy

A coated-pellet system can use:

• A drug-loaded sugar sphere or neutral core
• A hydrophilic seal coat
• An ethylcellulose-based rate-controlling membrane
• Hypromellose or povidone as a binder or pore-forming component
• A hard gelatin or hydroxypropyl methylcellulose capsule shell

This approach is commercially practical because the manufacturing process is established across many extended-release products. The main development variables are coating weight gain, polymer ratio, pore former level, curing conditions, pellet size, and capsule fill weight.

A product developer should target a dissolution profile that avoids an early concentration spike while preserving sufficient exposure during the dosing interval. The formulation must also demonstrate robustness against:

• Alcohol-induced dose dumping
• Food-related changes in gastric emptying
• Mechanical stress during manufacturing and shipping
• Capsule shell variability
• Changes in coating equipment or scale

Hydrophilic matrix strategy

A hydrophilic matrix tablet or mini-tablet could use high-viscosity hypromellose, polyethylene oxide, or related matrix-forming polymers. This approach may reduce coating operations and lower manufacturing cost. It could also support tablets, capsules containing mini-tablets, or sprinkle-compatible presentations.

The principal weakness is that cyclobenzaprine ER is commercially associated with a capsule-based multiparticulate profile. A matrix tablet would need comparative dissolution and pharmacokinetic evidence showing that the new release pattern is clinically acceptable. A matrix system also requires close control of tablet dimensions, compression force, polymer hydration, and erosion behavior.

Combination of immediate-release and extended-release populations

A capsule containing separate immediate-release and extended-release pellets could provide a small early fraction followed by prolonged exposure. The approach may help address onset-of-action expectations while retaining once-daily dosing. It creates added control requirements for:

• Fractional dose allocation
• Pellet segregation
• Uniformity of each release population
• Dissolution interaction between pellet types
• Bioequivalence and food-effect performance

This strategy is more defensible when it solves a clear clinical or adherence problem. It is less attractive if it only replicates the reference product without a meaningful pharmacokinetic or use benefit.

What formulation patents protect cyclobenzaprine HCl ER?

The original Amrix patent estate focused on extended-release formulations and controlled delivery of cyclobenzaprine. The central U.S. patent associated with the product was U.S. Patent No. 6,579,877, which covered extended-release cyclobenzaprine formulations and related delivery concepts. The patent was assigned to companies associated with the Amrix development and commercialization program and had an expiration date in the late 2010s or around 2020, subject to patent-term adjustments and any applicable extensions.[3]

IP category	Relevance to cyclobenzaprine HCl ER
Composition of matter	Limited value because cyclobenzaprine is an old active ingredient
Extended-release formulation	Historically central to Amrix protection
Pellet and coating architecture	Potentially relevant to design-around analysis
Method of treatment	May cover once-daily treatment or defined patient populations
Manufacturing process	Can protect drug layering, coating, curing, or pellet processing
Trade dress and trademarks	May protect branding but not the active formulation

Current freedom-to-operate analysis should focus on unexpired formulation, process, and method-of-use claims rather than the expired or expiring primary Amrix patents. A new product may reduce risk by using a different release mechanism, different excipient combination, different pellet architecture, and different claim language.

When does cyclobenzaprine ER lose exclusivity?

The major exclusivity period for Amrix has ended. The product is no longer protected by new-drug exclusivity in a way that prevents routine generic competition, and the relevant extended-release formulation patent protection has largely expired or reached the end of its commercial life.[3,4]

The practical exclusivity timeline is:

Period	Commercial implication
Pre-generic period	Amrix controlled the once-daily ER segment
Patent challenge period	ANDA applicants could file Paragraph IV certifications against listed patents
Post-expiration period	Generic ER products could enter subject to FDA approval
Current market	Competition is based on price, supply reliability, formulary access, and product differentiation

The exact generic entry date for each manufacturer depends on its ANDA approval, litigation outcome, settlement terms, and any 180-day exclusivity. The FDA Orange Book remains the controlling public source for listed patents and regulatory exclusivity status.[4]

What is the Orange Book status of Amrix?

The Orange Book identifies FDA-approved drug products, therapeutic equivalence information, listed patents, and applicable exclusivity data.[4] For a current transaction or launch decision, the relevant review should include:

1. NDA 021777 and its supplements.
2. Current patent listings associated with the reference product.
3. Any use codes attached to method-of-use patents.
4. Therapeutic-equivalence codes for approved generic ER products.
5. Patent-term expiration and pediatric-extension information.
6. Whether the proposed product is eligible for an ANDA or requires a 505(b)(2) application.

A generic product that matches the reference product in active ingredient, dosage form, strength, route, and release characteristics may qualify for an ANDA. A materially different delivery system, new dosing regimen, new indication, or clinically meaningful formulation change may require a 505(b)(2) application.

Which companies are challenging or competing with Amrix?

Competition comes from three groups:

• Manufacturers of generic cyclobenzaprine ER capsules
• Manufacturers of immediate-release cyclobenzaprine tablets
• Developers of alternative muscle-relaxant products, including tizanidine, baclofen, methocarbamol, and carisoprodol

The generic competitive landscape is fragmented compared with high-volume cardiovascular or metabolic drugs. Immediate-release cyclobenzaprine is usually the stronger price competitor because it is widely available and familiar to prescribers. ER products compete on adherence, dosing convenience, and pharmacy substitution rather than on active-ingredient novelty.

Publicly available FDA resources identify approved products and applicants, but they do not provide a complete real-time ranking of commercial market share by manufacturer.[4,5] Commercial diligence should therefore distinguish between approved ANDA holders, active suppliers, label owners, contract manufacturers, and companies with actual pharmacy distribution.

What commercial opportunities exist for cyclobenzaprine HCl ER?

Low-cost generic ER supply

The most direct opportunity is a reliable generic capsule with efficient pellet manufacturing and strong supply continuity. The market does not require a novel excipient system if the product has:

• Demonstrated bioequivalence
• Competitive cost of goods
• Stable dissolution across batches
• Reliable API supply
• Multiple qualified coating and packaging suppliers

Manufacturers can improve margin through high drug loading, shorter coating cycles, reduced solvent use, and process analytical technology that minimizes release testing failures.

505(b)(2) reformulation

A 505(b)(2) strategy may support a differentiated product with one or more of the following:

• Sprinkle-capable capsules
• Smaller capsules for swallowing difficulty
• Abuse-deterrent or tamper-resistant presentation
• Reduced sedation through altered exposure
• Alternative once-daily dose strengths
• Improved food-effect performance
• Liquid or orally disintegrating delivery for patients unable to swallow tablets

The clinical and regulatory value must exceed the cost of additional pharmacokinetic or clinical studies. A new capsule color or routine excipient substitution is unlikely to create a strong commercial position by itself.

Pediatric and geriatric delivery

Cyclobenzaprine ER is primarily used in adults and is not generally positioned as a pediatric chronic-treatment product. Pediatric development would face clinical, safety, and regulatory barriers because of the drug’s anticholinergic and sedating properties. A geriatric-oriented swallowability or dose-flexibility product is commercially more plausible, but it would still require careful labeling and safety positioning.

Combination products

A cyclobenzaprine ER combination with an analgesic or anti-inflammatory drug could improve convenience, but it would increase regulatory and safety complexity. Combination development would need to address dose titration, contraindications, drug-drug interactions, and the short-term indication of cyclobenzaprine.

What manufacturing and intellectual-property barriers remain?

The largest technical barrier is consistent release control at commercial scale. Important process risks include pellet agglomeration, coating defects, variable drug layering, electrostatic segregation, and dissolution drift after storage.

The main IP barriers are narrower than they were during the Amrix exclusivity period. They may still include:

• Unexpired claims covering a specific polymer system
• Process claims for drug-loaded pellets
• Method-of-use claims tied to dosing frequency
• Patent claims covering a particular dissolution profile
• Trade-secret protection over coating parameters and scale-up conditions

A design-around should begin with claim mapping against the active patent family, followed by comparative dissolution and pharmacokinetic development. Formulation changes that reduce patent risk can create new bioequivalence risk, so IP design and regulatory strategy must be developed together.

How strong is the cyclobenzaprine ER patent estate?

The estate is commercially weak as a barrier to ordinary generic entry because the active ingredient is old and the principal product-specific exclusivity has ended. Its remaining value lies in narrow formulation or process claims, if any remain enforceable in the relevant jurisdiction.

Patent factor	Assessment
Active-ingredient protection	Weak or expired
Original ER formulation protection	Largely expired
Generic entry barrier	Low to moderate, depending on current listings
Manufacturing know-how	Moderate
Formulation differentiation potential	Moderate
New-product patentability	Possible for defined delivery systems, but claim scope may be narrow

Patent protection for a new cyclobenzaprine ER product would be strongest when tied to a specific, reproducible technical feature such as a defined multiparticulate architecture, a controlled dissolution range, a novel abuse-deterrent system, or a clinically relevant pharmacokinetic advantage.

What biosimilar risk applies to cyclobenzaprine ER?

No biosimilar pathway applies. Cyclobenzaprine is a chemically synthesized small molecule, not a biologic. Competitive risk comes from ANDA-approved generics, 505(b)(2) reformulations, and substitution against immediate-release products.

What litigation and settlement issues affect cyclobenzaprine ER?

Historical litigation risk centered on Paragraph IV challenges to Amrix formulation patents. Once the relevant patent protection expired or became commercially immaterial, litigation ceased to be the primary market-control mechanism. Current diligence should verify whether any later-listed patents, pediatric extensions, use-code disputes, or settlement restrictions remain in the Orange Book or public court records.[4,6]

No broad biosimilar settlement framework applies, and no current settlement should be assumed to restrict generic entry without a specific court filing, FDA record, or definitive company disclosure.

How does cyclobenzaprine ER compare with immediate-release cyclobenzaprine?

Factor	ER cyclobenzaprine	IR cyclobenzaprine
Dosing	Once daily	Multiple daily doses
Formulation complexity	High	Low
Manufacturing cost	Higher	Lower
Adherence potential	Better	Lower
Generic price pressure	High	Very high
Differentiation basis	Release profile and convenience	Price and availability
Patent opportunity	Delivery-system claims	Limited
Main commercial risk	Generic ER substitution and IR switching	Commodity pricing

The commercial case for ER depends on preserving a clear dosing or tolerability advantage. Without that advantage, prescribers and payers may favor lower-cost immediate-release tablets.

Key Takeaways

• Cyclobenzaprine HCl ER is a mature product with limited remaining primary patent protection.
• The most credible excipient platform is a multiparticulate coated-pellet capsule using hypromellose, ethylcellulose, binders, inert cores, and standard capsule excipients.
• The main development risks are dose dumping, food effects, coating variability, and dissolution drift.
• Generic ER supply is the lowest-risk commercial opportunity.
• 505(b)(2) opportunities require a meaningful benefit such as improved swallowability, dose flexibility, food-effect control, or differentiated pharmacokinetics.
• Biosimilar risk does not apply because cyclobenzaprine is a small molecule.
• Immediate-release cyclobenzaprine remains the principal price competitor.
• New patent value is most likely to come from specific delivery systems, manufacturing processes, or clinically relevant release profiles.

FAQs

Is cyclobenzaprine HCl ER still protected by patents?

The major Amrix formulation patent protection has largely expired or reached the end of its commercial life. Current patent status must be checked against the FDA Orange Book and relevant patent records.

Can a cyclobenzaprine ER capsule be developed through an ANDA?

Yes, if the product matches the reference drug in the required pharmaceutical characteristics and demonstrates bioequivalence. A materially different delivery system may require a 505(b)(2) pathway.

Which polymer is most useful for cyclobenzaprine extended release?

Ethylcellulose is suitable for diffusion-controlled coating, while hypromellose can function as a binder, film former, or hydrophilic release-control polymer. The final choice depends on the target dissolution profile and manufacturing process.

Is cyclobenzaprine ER suitable for an abuse-deterrent formulation?

It is technically possible, but the commercial and regulatory justification would depend on evidence of abuse risk, the selected technology, and whether the formulation creates a meaningful safety benefit.

What is the strongest patent strategy for a new cyclobenzaprine ER product?

A narrow patent directed to a defined multiparticulate architecture, dissolution profile, manufacturing process, or clinically demonstrated pharmacokinetic advantage is more defensible than a broad claim covering routine excipient substitution.

References

1. U.S. Food and Drug Administration. (n.d.). Amrix (cyclobenzaprine hydrochloride) extended-release capsules: Prescribing information. Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. United States Patent and Trademark Office. (2003). U.S. Patent No. 6,579,877: Extended release formulations of cyclobenzaprine. Washington, DC.

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

6. U.S. Food and Drug Administration. (n.d.). Paragraph IV patent certifications and generic drug patent information. FDA Center for Drug Evaluation and Research.